Sire Bioscience Inc. (“SIRE”) (CSE:SIRE) (OTC:BLLXF) (FSE:BR1B) (“Sire” or the “Company”) announces that, as a result of the COVID-19 pandemic, it will be relying on the coordinated relief provided by the securities regulators which consists of a 45-day extension for certain periodic filings, as announced by the Canadian Securities Administrators (“CSA”) on March 18, 2020, with respect to the filing of its interim financial statements, management’s discussion and analysis, and related officer certificates for its second quarter ended March 31, 2020. The notice released by the CSA stated that securities regulators will be providing coordinated relief consisting of a 45-day extension for certain periodic filings required to be made on or prior to June 1, 2020 as a result of the COVID-19 pandemic. As such, the British Columbia Securities Commission (“BCSC”) has enacted BC Instrument 51-515, Temporary Exemption from Certain Corporate Finance Requirements (“BCI 51-515”). The Company will be relying on the temporary exemption pursuant to BCI 51-515 in respect to the following provisions: the requirement to file interim financial statements for the six months ended March 31, 2020 (the “Financial Statements”) within 60 days after the end of the Company’s interim period as required by section 4.4(b) of National Instrument 51-102 Continuous Disclosure (“NI 51-102”); the requirement to file management discussion and analysis (the “MD&A”) for the period covered by the Financial Statements within 60 days after the end of the Company’s interim period as required by section 5.1(2) of NI 51-102; and the requirement to file certifications of the Financial Statements (the “Certificates” and together with the Financial Statements, the “Interim Filings”) pursuant to section 5.1 of National Instrument 52-109 Certification of Disclosure in Issuer’s Annual and Interim Filings and section 4.4(b) [being the filing deadline for interim financial statements] of NI 51-102.
The Company is continuing to work diligently to file the Interim Filings by July 16, 2020. The Company confirms that there have been no material developments, other than those disclosed through news releases and Form 7 Monthly Progress Reports filed on the Company’s profile with the Canadian Securities Exchange, since the filing of its condensed interim consolidated financial statements for the three months ended March 31, 2020. Additionally, the Company advises that management and other insiders of the Company are subject to a trading black-out policy as described, in principle, in section 9 of National Policy 11-207, Failure to-File Cease Trade Orders and Revocations in Multiple Jurisdictions. About Sire Bioscience SIRE’s principal business activity is to engage in the investment, production of, and sale of hemp. Its mission is to execute on brand offerings that connect with people and build top of mind awareness. SIRE is headquartered in Mississauga, Ontario and is backed by a group of successful entrepreneurs who have extensive experience in the areas of manufacturing, consumer packaged goods, logistics, and distribution. It has secured a state-of-the-art agricultural facility in Leamington, Ontario – a preeminent locale for hemp cultivation in Canada.
FOR INFORMATION, CONTACT:
Sire Bioscience Inc. E: firstname.lastname@example.org
The CSE and Information Service Provider have not reviewed and does not accept responsibility for the accuracy or adequacy of this release.
HempFusion Wellness Inc. Files Preliminary Prospectus for Initial Public Offering of Common Shares and Units
HempFusion Wellness Inc. (“HempFusion”), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce that it has filed a preliminary prospectus (the “Preliminary Prospectus”) with the securities regulatory authorities in each of the provinces of Canada, except Quebec, for a proposed initial public offering of (i) common shares of the Company (the “Offered Shares”) for gross proceeds of up to USD$7,000,000 (the “Share Offering”) and (ii) units of the Company (the “Units”) for gross proceeds of up to USD$10,000,000 (the “Unit Offering” and together with the Share Offering, the “Offering”). The offering price of the Offered Shares and the Units (the “Offering Price”) will be determined in the context of the market and is anticipated to be between USD$0.90 and USD$1.35 (the “Offering Price”) per Offered Share and per Unit, respectively.
“We are incredibly excited to announce our initial public offering and HempFusion’s intention to list its securities on the Toronto Stock Exchange. To be the first US-based CBD company to apply to list on the TSX is a tremendous honour,” stated HempFusion’s CEO, Dr. Jason Mitchell N.D. “Completion of this proposed initial public offering will accelerate our ability to scale HempFusion’s operations both domestically and internationally, drive accelerated growth within all our distribution channels, and significantly expand our marketing initiatives,” continued Mitchell.
Trading resumes in:
Company: Harvest Health & Recreation Inc.
** THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.**
Harvest Health & Recreation Inc. (“Harvest” or the “Company”) ( CSE: HARV ), a vertically integrated cannabis company and multi-state operator in the U.S., is pleased to announce that is has entered into an amended agreement with Eight Capital, pursuant to which Eight Capital, together with Canaccord Genuity Corp., as co-lead underwriters and joint bookrunners, together with a syndicate of underwriters (collectively, the “ Underwriters ”), will now purchase on a “bought deal” basis 17,699,200 units of the Company (“the Units ”) at a price of $2.26 per Unit (the “ Offering Price ) for aggregate gross proceeds to Harvest of $40,000,192 (the “ Offering ”). (All figures are in Canadian dollars unless otherwise stated.)
Heritage Cannabis Holdings Corp. (CSE: CANN) (OTCQX: HERTF) (“Heritage” or the “Company”), is pleased to announce that both Pura Vida and Purefarma tinctures will be available for purchase next week in the province of British Columbia through the province’s authorized Liquor Distribution Branch (“LDB”) channels.
BC Customers will soon be able to purchase Pura Vida Daybreak and Nightfall tinctures as well as Purefarma HLX30 CBD and Balance 15:15. Heritage launched both Pura Vida and Purefarma vape cartridges in September 2020 and the response by customers has been tremendous in the two provinces in which they are available British Columbia and Manitoba.
Numinus Bioscience’s developments include harvesting its first flush of Psilocybe mushrooms at its Health Canada licensed facility.
Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a company creating an ecosystem of health solutions centred on developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies, has harvested the first legal flush of Psilocybe mushrooms in Canada by a public company under its Health Canada-issued Controlled Drugs and Substances Dealer’s Licence. This news coincides with other recent developments by Numinus Bioscience, the Company’s 7,000 square foot analytics and research laboratory, which is focused on handling various psychedelic substances and developing analytical methods and formulations for the evolving psychedelics space.